Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET
Company Participants
MarDee Haring-Layton – CAO
Sabrina Martucci Johnson – President and CEO
Conference Call Participants
Catherine Novack – JonesTrading
Brian Kemp Dolliver – Brookline Capital Markets
Douglas Tsao – H.C. Wainwright
Operator
Welcome to the conference call hosted by Daré Bioscience to review the company’s Third Quarter Financial Results and to provide a general business update. This call is being recorded. My name is Desiree and I will be your operator today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer and MarDee Haring-Layton, Chief Accounting Officer.
Ms. Haring-Layton. Please proceed.
MarDee Haring-Layton
Good afternoon and welcome to the Daré Bioscience financial results and business update call for the quarter ended September 30, 2024. Today we will review our third quarter results and discuss developments and expectations for our pipeline and portfolio.
I would like to remind you that today’s discussion will include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking statements.
Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by cautionary statements in the company’s SEC filings, including our Form 10-Q for the quarter ended September 30, 2024 which was filed today.
I would also like to point out that the content of this call includes time sensitive information that is current only as of today, November 14, 2024. Daré undertakes no obligation to
Credit: Source link
